

Food and Drug Administration - Shortage of amphetamine mixed salts

- On October 12, 2022, the <u>FDA announced</u> a shortage of the immediate release formulation of amphetamine mixed salts, commonly referred to by the brand name Adderall[®] or Adderall IR.
- Brand and generic Adderall are FDA-approved for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. Amphetamine products are CII controlled substances.
- Increased utilization and has led to constricted supply that is impacting generic and brand products, as well as immediate and sustained release products.
- The FDA is in frequent communication with all manufacturers of amphetamine mixed salts. Some
 companies are experiencing ongoing intermittent manufacturing delays, but other manufacturers
 continue to produce amphetamine mixed salts products. The overall supply is volatile, but product
 is available, and pharmacies are able to fill prescriptions, however periodic delays may occur until
 the supply is fully restored.
- Until supply is restored, there are alternative therapies including the extended-release version of amphetamine mixed salts available to health care providers and their patients for amphetamine mixed salts' approved indications. Patients should work with their health care professionals to determine their best treatment option.
- The <u>FDA shortage site</u> provides updates on the shortage, including a list of current manufacturers and product strengths that are still available.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.